Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.90 |
| ▸ | BLM | P54132 | 2/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.90 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.90 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | POLB | P06746 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.83 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | MTOR | P42345 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155582 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5088067 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8373082 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| Nonivamide SCHEMBL81939 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL679954 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2400979 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5889449 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1155739 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6409250 | 0.95 | CYP1A2 (0.81) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| Nonivamide SCHEMBL29425552 | 0.95 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244767-B2 | N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors | INNOVET ITALIA S.R.L. (IT) | 2007-07-17 | — | — | US | claimed |
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | INNOVET ITALIA S.R.L. (IT) | 2005-03-24 | — | — | US | claimed |
| EP-1115392-B1 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA SRL (IT) | 2002-12-11 | — | — | EP | claimed |
| US-7244767-B2 | N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors | INNOVET ITALIA S.R.L. (IT) | 2007-07-17 | — | — | US | disclosed |
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | INNOVET ITALIA S.R.L. (IT) | 2005-03-24 | — | — | US | disclosed |
| EP-1115392-B1 | USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS | INNOVET ITALIA SRL (IT) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065216-A1 | Therapy for multiple sclerosis, psoriasis, urticaria; antiarthritic agents; incotinence; antitumor, anticancer agents | CNR1, CNR2, GPR18 | CYP1A2 3643/4885CYP3A4 4294/4885CYP2D6 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.